This is interesting: Claude is already achieving roughly twice the protein-design hit rate of conventional human-led workflows. 27% hit rate in autonomous protein binder design, roughly twice the typical 10–15% rate reported in the field.
Working from one expert-written protocol, Claude designed binders against 14 of 15 measurable targets. Independent labs confirmed that 354 of 1,320 designs bound successfully.
Depending on the setup, Claude’s hit rate ranged from 22.6% to 35.1%. Its top-ranked design bound in 49% of campaigns.
This is not yet fully autonomous drug research, but it is another important building block in that direction.
Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is de...